483
Views
5
CrossRef citations to date
0
Altmetric
Editor’s Choice

Psychiatrists’ attitudes towards and willingness to prescribe cognitive enhancers in academic settings

, , , , , & show all
Pages 59-66 | Received 12 Aug 2019, Accepted 21 Feb 2020, Published online: 10 Mar 2020
 

Abstract

Cognitive enhancers (CEs) such as methylphenidate, dexamphetamine and modafinil are increasingly used beyond their prescribed indications by healthy individuals without medical necessity, in academic settings. Prescribing of these stimulant medicines have increased over the last decade.

Aim

To explore psychiatrists’ attitudes towards the use of CEs in academic settings, and their willingness to prescribe CEs.

Methods

The study was conducted via an anonymous, paper-based questionnaire sent to a random sample of 200 psychiatrists in New Zealand. The questionnaire assessed demographics and knowledge of CEs, attitudes towards the use of CEs in healthy individuals, perceptions on the extent of use by university students and attitudes towards, and willingness to prescribe CEs.

Results

Of the 200 questionnaires distributed, 81 completed questionnaires were returned, giving a response rate of 40.5% (81/200). Although 19.8% of participants reported receiving requests from university students for CEs, only 6.1% reported prescribing medicines for university students that they considered were for cognitive enhancement. None of the participants would routinely prescribe methylphenidate to a healthy university student. Reasons for not prescribing CEs included concern for safety, being unethical, and not warranted in the absence of illness.

Conclusion

Psychiatrists are aware of the use of CEs by students and play a crucial role in prescribing or curbing its use. There was a lack of consensus within the profession on attitudes towards efficacy, the safety of CEs when prescribed and potential for adverse outcomes.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.